Toll-like receptors and atherosclerosis: key contributors in disease and health?
about
Identification of potential pathway mediation targets in Toll-like receptor signalingIncreased endothelial expression of Toll-like receptor 2 at sites of disturbed blood flow exacerbates early atherogenic events.Diabetes is a proinflammatory state: a translational perspective.Cathepsin L promotes Vascular Intimal Hyperplasia after Arterial InjuryGlutathione peroxidase-1 modulates lipopolysaccharide-induced adhesion molecule expression in endothelial cells by altering CD14 expression.Demonstration of increased toll-like receptor 2 and toll-like receptor 4 expression in monocytes of type 1 diabetes mellitus patients with microvascular complications.The role of hyperglycemia in mechanisms of exacerbated inflammatory responses within the oral cavityToll-like receptors (TLRs) in transplantationIncreased toll-like receptor activity in patients with metabolic syndromeHyperglycemia induces Toll like receptor 4 expression and activity in mouse mesangial cells: relevance to diabetic nephropathy.Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state.Short-term exercise training improves insulin sensitivity but does not inhibit inflammatory pathways in immune cells from insulin-resistant subjects.Cell-penetrating TIR BB loop decoy peptides a novel class of TLR signaling inhibitors and a tool to study topology of TIR-TIR interactions.Innate immunity and aging.Upregulation of inflammatory gene transcripts in periosteum of chronic migraineurs: Implications for extracranial origin of headache.Increased levels of ligands of Toll-like receptors 2 and 4 in type 1 diabetesPioglitazone inhibits Toll-like receptor expression and activity in human monocytes and db/db mice.Effects of chronic mild stress on the development of atherosclerosis and expression of toll-like receptor 4 signaling pathway in adolescent apolipoprotein E knockout mice.Expression of toll-like receptor 4 in maternal monocytes of patients with gestational diabetes mellitus.Increased secretion of IP-10 from monocytes under hyperglycemia is via the TLR2 and TLR4 pathway.Host cholesterol and inflammation as common key regulators of toxoplasmosis and artherosclerosis development.Novel risk factors for cardiovascular disease in rheumatoid arthritis.Impact of Systemic Inflammation on the Progression of Gestational Diabetes Mellitus.Mechanisms of erosion of atherosclerotic plaques.Atorvastatin inhibits functional expression of proatherogenic TLR2 in arterial endothelial cells.The biological effects of CRP are not attributable to endotoxin contamination: evidence from TLR4 knockdown human aortic endothelial cells.miR-223 Inhibits Lipid Deposition and Inflammation by Suppressing Toll-Like Receptor 4 Signaling in Macrophages.Role of MyD88-dependent and MyD88-independent signaling in Porphyromonas gingivalis-elicited macrophage foam cell formation.Candesartan inhibits Toll-like receptor expression and activity both in vitro and in vivo.Toll-like receptor activity in patients with obstructive sleep apnea.
P2860
Q28474725-06F0DF1E-F09F-4F83-AE3C-B51313D74272Q33318184-06EFF1BB-C521-4D73-9AAC-5CE7BFD67492Q33693974-D96CF542-878D-4459-BDA0-5933440AD68FQ33789216-BE79205D-5313-4997-9357-FDEED6D1FC67Q33919459-850813B0-4505-479D-837E-A7D3E4AB49C3Q33937994-E43A0E93-58B7-41BD-853C-A7060E206643Q35564034-3A9D680B-8633-404C-894C-2A9D39D0CF38Q35581147-12619DB2-F71C-4EAA-801D-63D637D1E70BQ35841261-ADA307F1-0C79-476F-B0AD-D313040EBE88Q36312635-D3C85488-6241-4159-A754-AF58E42874BEQ36459935-D6AD8C34-7926-4087-8567-557AA331745EQ36825685-352B597F-5CED-4A20-8BF2-20E59280690CQ36897400-143BD1DF-C319-4166-9246-71A8ED2554C0Q36929586-684431CC-303C-4987-90AA-5DC3436E4316Q36944764-A7BE0434-F234-4493-B5BF-33D0249831FFQ37259921-99184560-9043-497B-966B-0FF58DC1353DQ37281187-FF42E301-D788-4890-BC01-8258D07F3AF0Q37326042-10E78224-B1F5-4C7B-BFF4-BCDB24861780Q37388603-8B63270D-7D60-4C37-ADDB-A55A22CDD416Q37408117-AE772084-8BE2-4FD7-AA74-F1D807E70D7DQ37593102-152D157A-16EC-42FB-BBB4-0A7F6113DF8AQ38098935-04686BA1-2BB7-435A-8165-A84CBEC7DF1DQ38734509-8570DFAC-9403-4B02-A9CA-89CC2FCA860BQ39418237-64F0CF94-570B-42BF-8B77-4F2E9A293DD2Q39426447-AA320087-C7A3-4C05-87B9-A0114D3E6EE9Q40198481-A5EFD159-9683-43DE-9F6F-604352681E77Q40402994-2AF37835-64CF-4113-9242-6BA67D3D795CQ41894655-104CB1D3-AC72-40A9-8311-75E9EA6FD5EDQ41969861-C92F83CE-46FA-405A-A999-4F1072C65BBBQ45323315-EBFE175B-5EDF-4647-B87A-E5863AC95E2E
P2860
Toll-like receptors and atherosclerosis: key contributors in disease and health?
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Toll-like receptors and atherosclerosis: key contributors in disease and health?
@ast
Toll-like receptors and atherosclerosis: key contributors in disease and health?
@en
type
label
Toll-like receptors and atherosclerosis: key contributors in disease and health?
@ast
Toll-like receptors and atherosclerosis: key contributors in disease and health?
@en
prefLabel
Toll-like receptors and atherosclerosis: key contributors in disease and health?
@ast
Toll-like receptors and atherosclerosis: key contributors in disease and health?
@en
P356
P1433
P1476
Toll-like receptors and atherosclerosis: key contributors in disease and health?
@en
P2093
Linda K Curtiss
Peter S Tobias
P2888
P304
P356
10.1385/IR:34:3:193
P577
2006-01-01T00:00:00Z
P6179
1041369262